Mesoblast Limited (ASX:MSB – Get Free Report) insider Eric Rose sold 196,092 shares of the company’s stock in a transaction dated Friday, February 28th. The stock was sold at an average price of A$2.50 ($1.58), for a total value of A$489,445.63 ($309,775.72).
Eric Rose also recently made the following trade(s):
- On Thursday, January 16th, Eric Rose acquired 30,310 shares of Mesoblast stock. The stock was acquired at an average cost of A$16.70 ($10.57) per share, with a total value of A$506,207.31 ($320,384.37).
Mesoblast Price Performance
The stock has a market cap of $2.32 billion, a PE ratio of -23.29, a P/E/G ratio of 9.56 and a beta of 2.38. The company has a debt-to-equity ratio of 24.76, a current ratio of 1.18 and a quick ratio of 1.82.
About Mesoblast
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Featured Articles
- Five stocks we like better than Mesoblast
- What Do S&P 500 Stocks Tell Investors About the Market?
- Institutional Investors Bet $1B on These 4 Stocks—Should You?
- How to Evaluate a Stock Before Buying
- One Must-Buy Stock and One to Avoid as Tariffs Shake the Market
- The Role Economic Reports Play in a Successful Investment Strategy
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.
